Haemonetics' Roy Galvin has 146 shares withheld

The reported 39,805-share position includes unvested restricted stock units and 69 shares acquired on October 31, 2026, through the employee stock purchase plan.

Available on EDGAR 11/03/2026 - 04:16 PM EST Accepted by SEC EDGAR 11/03/2026 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Haemonetics Corp. EVP, Chief Commercial Officer Roy Galvin had 146 shares withheld for tax obligations in connection with the vesting of previously reported restricted stock units on October 30, 2026. The reported price was $119.65 per share. His direct holdings following the transaction were 39,805 shares; that figure includes unvested RSUs and 69 shares acquired on October 31, 2026, under the Haemonetics Corporation 2007 Employee Stock Purchase Plan.

Insider Trade Summary

Tax Withholding: 146 shares

Tax Withholding 1 txn

Insider Galvin Roy

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1, F2	146	$119.65	$17K

Holdings After Transaction: Common Stock — 39,805 shares (Direct)

Holdings Before and After: Common Stock, 39,951 to 39,805 shares (Direct)

Footnotes (2)

1. F1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
2. F2. This number includes unvested RSUs previously reported as well as 69 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on October 31, 2026.

Key Figures

Shares withheld for tax obligations: 146 shares Reported price per share: $119.65 per share Direct holdings following transaction: 39,805 shares +1 more

4 metrics

Shares withheld for tax obligations 146 shares October 30, 2026; in connection with vesting of previously reported RSUs

Reported price per share $119.65 per share Transaction reported for October 30, 2026

Direct holdings following transaction 39,805 shares Includes unvested RSUs and 69 shares acquired October 31, 2026

Shares acquired under employee stock purchase plan 69 shares Acquired October 31, 2026

Key Terms

restricted stock units, vesting, Employee Stock Purchase Plan

3 terms

restricted stock units financial

"vesting of certain restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"in connection with the vesting of certain restricted stock units"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Employee Stock Purchase Plan financial

"Haemonetics Corporation 2007 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Roy Galvin report for HAE?

Roy Galvin had 146 shares withheld for tax obligations on October 30, 2026, in connection with vesting of previously reported restricted stock units; the reported price was $119.65 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galvin Roy

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2026		F		146(1)	D	$119.65	39,805(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

2. This number includes unvested RSUs previously reported as well as 69 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on October 31, 2026.

	/s/ Thomas V. Powers, attorney-in-fact for Mr. Galvin	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)